Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

1. Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study.Cancer · 2020
   Article
2. Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020
   Review
3. Treatment-related acute granulocyte-monocytic leukemia from multiple myeloma: A case report and literature review.Medicine · 2017
   Review
4. The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.Blood advances · 2017
   Article
5. [Multiple myeloma associated with myeloid tumor: 5 cases report and literatures review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017
   Article
6. AML transformation after autologous stem cell transplant for multiple myeloma.BMJ case reports · 2015
   Article
7. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.Clinical lymphoma, myeloma & leukemia · 2015
   Article
8. Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.Leukemia · 2014
   Article
9. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.Leukemia & lymphoma · 2013
   Article
10. Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study.PloS one · 2013
    Article
11. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?Haematologica · 2012
    Article
12. Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.Advances in hematology · 2012
    Article
13. Myeloma and second primary cancers.The New England journal of medicine · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 5 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as